首页|期刊导航|中国合理用药探索|多西环素与阿奇霉素联合甲泼尼龙治疗儿童难治性肺炎支原体肺炎的疗效对比研究

多西环素与阿奇霉素联合甲泼尼龙治疗儿童难治性肺炎支原体肺炎的疗效对比研究OA

Comparative Study on the Efficacy of Doxycycline and Azithromycin Combined with Methylprednisolone in the Treatment of Refractory Mycoplasma pneumoniae Pneumonia in Children

中文摘要英文摘要

目的:对比多西环素与阿奇霉素联合甲泼尼龙治疗儿童难治性肺炎支原体肺炎(RMPP)的疗效.方法:前瞻性选取 2023 年 7月~2024年12 月于本院诊治的108例RMPP 患儿作为研究对象,采用随机数字表法分为对照组(n=54)和观察组(n=54).对照组给予阿奇霉素联合甲泼尼龙治疗,观察组给予多西环素联合甲泼尼龙治疗.比较两组临床疗效、临床症状消退时间、住院时间、炎性因子[C反应蛋白(CRP)、白介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)]、肺功能[第1秒用力呼气容积(FEV1)实测值占预计值的百分比、FEV1/用力肺活量(FVC)、呼气流量峰值(PEF)实测值占预计值的百分比]及不良反应发生情况.采用 Modeler 软件对患儿临床疗效和不良反应的影响因素进行数据挖掘.结果:观察组临床治疗总有效率(90.74%)高于对照组(75.93%),临床症状(发热、咳嗽、喘息、肺部啰音)消退时间、住院时间均短于对照组(P<0.05).治疗后,观察组 CRP、IL-10 和 TNF-α均低于对照组,FEV1 实测值占预计值的百分比、FEV1/FVC、PEF 实测值占预计值的百分比均高于对照组(P<0.05).治疗期间,两组不良反应总发生率比较无统计学差异(P>0.05).经 Modeler 软件自动分类器模型分析,治疗前 TNF-α、治疗前 FEV1 实测值占预计值的百分比和治疗前 CRP 是影响临床疗效的核心驱动因素.经 Modeler 软件贝叶斯网络模型分析,性别、年龄、体重、治疗前发热持续时间是影响不良反应发生的关键因素.结论:多西环素联合甲泼尼龙治疗儿童 RMPP 的疗效优于阿奇霉素联合甲泼尼龙,能有效缩短临床症状时间、减轻炎症反应及改善肺功能.

Objective:To compare the efficacy of doxycycline and azithromycin combined with methylprednisolone in the treatment of refractory Mycoplasma pneumoniae pneumonia(RMPP)in children.Methods:A total of 108 children with RMPP diagnosed and treated in our hospital from July 2023 to December 2024 were prospectively selected as study subjects and divided into a control group(n=54)and an observation group(n=54)using a random number table method.The control group was treated with azithromycin combined with methylprednisolone,while the observation group was treated with doxycycline combined with methylprednisolone.The clinical efficacy,time to clinical symptom resolution,length of hospital stay,inflammatory markers[C-reactive protein(CRP),interleukin-10(IL-10),tumor necrosis factor-α(TNF-α)],pulmonary function[percentage of forced expiratory volume in one second(FEV1)to predicted value,FEV1/forced vital capacity(FVC),percentage of peak expiratory flow(PEF)to predicted value],and incidence of adverse reactions were compared between the two groups.Data mining was performed using Modeler software to analyze the influencing factors of clinical efficacy and adverse reactions in children.Results:The total effective rate in the observation group(90.74%)was higher than that in the control group(75.93%),and the time to clinical symptom resolution(fever,cough,wheeze,and lung rale)and length of hospital stay were shorter in the observation group than in the control group(P<0.05).After treatment,CRP,IL-10,and TNF-α levels were lower in the observation group,while the percentage of FEV1 to predicted value,FEV1/FVC,and percentage of PEF to predicted value were higher in the observation group than in the control group(P<0.05).During treatment,there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).According to the automatic classifier model of Modeler software,TNF-α before treatment,percentage of FEV1 to predicted value before treatment,and CRP before treatment were the core driving factors affecting clinical efficacy.According to the Bayesian network model analysis of Modeler software,gender,age,body mass,and the duration of fever before treatment were key factors influencing the incidence of adverse reactions.Conclusion:The efficacy of doxycycline combined with methylprednisolone in the treatment of pediatric RMPP is superior to that of azithromycin combined with methylprednisolone,effectively shortening the duration of clinical symptoms,reducing inflammatory response,and improving lung function.

裴留伟;张晓环;朱少娟

许昌市妇幼保健院儿科,许昌 461000许昌市妇幼保健院儿科,许昌 461000许昌市妇幼保健院儿科,许昌 461000

医药卫生

多西环素阿奇霉素甲泼尼龙难治性肺炎支原体肺炎肺功能炎性因子

doxycyclineazithromycinmethylprednisolonerefractory Mycoplasma pneumoniae pneumonialung functioninflammatory factor

《中国合理用药探索》 2026 (5)

44-51,8

10.3969/j.issn.2096-3327.2026.05.006

评论